PTEN and small cell lung carcinoma: To identify the additional target pathways of LSD1 independent of androgen treatment, we treated LNCaP cells (an androgen-responsive PCa cells line with PTEN loss) under hormone-depleted condition with a clinical tested LSD1 inhibitor, GSK2879552 (Phase I for small cell lung cancer) (15), at lower doses (1 or 5 μM) but for extended period of time (~2 weeks), and then carried out RNA-seq analyses.